Adults 18 to 45, female only, with Contraception or Tuberculosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Serum Etonogestrel ConcentrationsPrimary· 2 weeks
Blood drawn before and after rifampin administration (2 weeks) for serum extraction and etonogestrel analysis
Baseline
Group
Value
95% CI
Rifampin 600 mg
164.0
94.4 – 265.0
Post-rifampin
Group
Value
95% CI
Rifampin 600 mg
47.8
24.7 – 82.8
Sponsor's own description
It is important for women taking rifampin to be aware if they are at greater risk of an unintended pregnancy while on the implant. An unintended pregnancy has many social, emotional, and financial impacts on women and society. Rifampin is also a Class C medication for pregnancy and could have potential negative effects on a developing fetus. Additionally, women considering rifampin for treatment of LTBI face additional risks with an unintended pregnancy, making the reliability of contraception even more important for these women. The results of this study can directly inform counseling on a national and international basis for women who use the contraceptive implant and are considering their treatment options for LTBI.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07365904 — Investigating Ovulation Inhibition for Use as a Contraceptive
· Phase 2
· recruiting
NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period
· active not recruiting
NCT06823037 — Hormonal Contraception Access Through Pharmacist Prescribing Implementation
· NA
· recruiting
NCT07326007 — Verbal Analgesia Versus Standard Technique for Pain Control During Copper T380A Intrauterine Device Insertion in Women W
· NA
· recruiting
NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
· NA
· recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
· not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
· Phase 3
· not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.
· NA
· not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
· EARLY_PHASE1
· not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes
· Phase 2
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 16 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04463680.